Skip to main content
. Author manuscript; available in PMC: 2023 Jun 12.
Published in final edited form as: Mol Cancer Ther. 2022 Apr 1;21(4):535–545. doi: 10.1158/1535-7163.MCT-21-0728

Fig.6. Gemcitabine resistant PDAC cells remain sensitive to MMRi62 in vitro.

Fig.6.

A, Combination index (CI) plots for Panc1 cells (top) and BxPc3 cells (bottom) derived from dose-effect data of MMRi62 combination with gemcitabine in 72h proliferation assay. Gem, gemcitabine. CI <1, synergism, CI=1, additive, CI>1, antagonism. B, drug response curves of BxPc3 and Gem-R-BxPc3 cells to gemcitabine (top) and to MMRi62 (bottom, IC50=2.38±0.88 and 3.72±0.36μM, respectively for BxPc3 and Gem-R-BxPc3). C, drug response curves of HPAFII and Gem-R-HPAFII cells to gemcitabine (top) and to MMRi62 (bottom, IC50=4.04±0.59 and 6.62±0.52μM, respectively for HPAFII and Gem-R-HPAFII).

HHS Vulnerability Disclosure